JULIO
CORTIJO GIMENO
CATEDRÁTICO/A DE UNIVERSIDAD
Universidad San Jorge
Zaragoza, EspañaUniversidad San Jorge-ko ikertzaileekin lankidetzan egindako argitalpenak (3)
2022
-
Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 4, pp. 637-646
2021
-
Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: A cost-effectiveness analysis
Journal of Comparative Effectiveness Research, Vol. 10, Núm. 4, pp. 325-335
2019
-
Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: A cost-effectiveness analysis
Journal of Comparative Effectiveness Research, Vol. 8, Núm. 11, pp. 853-863